Motco boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 123,474 shares of the biopharmaceutical company’s stock after acquiring an additional 14,003 shares during the quarter. Motco’s holdings in Pfizer were worth $4,436,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the stock. Bath Savings Trust Co raised its position in Pfizer by 3.4% in the 2nd quarter. Bath Savings Trust Co now owns 17,217 shares of the biopharmaceutical company’s stock worth $746,000 after buying an additional 564 shares during the last quarter. Cox Capital Mgt LLC increased its position in shares of Pfizer by 1.5% during the 2nd quarter. Cox Capital Mgt LLC now owns 37,986 shares of the biopharmaceutical company’s stock valued at $1,646,000 after purchasing an additional 565 shares during the last quarter. Thomasville National Bank increased its position in shares of Pfizer by 4.1% during the 2nd quarter. Thomasville National Bank now owns 76,628 shares of the biopharmaceutical company’s stock valued at $3,319,000 after purchasing an additional 3,001 shares during the last quarter. Park National Corp OH increased its position in shares of Pfizer by 27.6% during the 2nd quarter. Park National Corp OH now owns 252,546 shares of the biopharmaceutical company’s stock valued at $10,941,000 after purchasing an additional 54,642 shares during the last quarter. Finally, Deane Retirement Strategies Inc. increased its position in shares of Pfizer by 1.8% during the 2nd quarter. Deane Retirement Strategies Inc. now owns 51,699 shares of the biopharmaceutical company’s stock valued at $2,240,000 after purchasing an additional 894 shares during the last quarter. Institutional investors own 71.52% of the company’s stock.
Shares of NYSE:PFE traded down $0.20 during mid-day trading on Monday, reaching $36.85. 7,668,247 shares of the company traded hands, compared to its average volume of 23,366,957. The company’s 50 day moving average price is $36.62 and its 200-day moving average price is $39.26. The firm has a market cap of $207.30 billion, a PE ratio of 12.28, a PEG ratio of 2.11 and a beta of 0.67. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $46.47.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.13. The company had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. The firm’s revenue was down 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.78 EPS. On average, research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.91%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
Several research firms have recently commented on PFE. Bank of America began coverage on shares of Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target for the company. UBS Group reaffirmed a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Morgan Stanley reduced their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 27th. Finally, DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a research report on Wednesday, August 28th. Nine analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $44.02.
In other Pfizer news, Director Scott Gottlieb purchased 3,000 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was acquired at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $104,160. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Pfizer Inc purchased 50,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Dividend Aristocrat Index
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.